- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02206178
Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine (PANACE)
ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE
Acetaminophen is one of the most widely used analgesic in the world, recommended for the symptomatic treatment of fever and pain.
The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.
The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine
- - decrease the antinociceptive effect of acetaminophen in comparison to a group control
- - and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Period 1 : To Day -4 to Day 0
Day -4 at 8:00 am at Clinical Pharmacology Center
- Inclusion Visit, signature of Informed consent form, clinical exam.
- Training test
- Blood sample (GSH, pharmacogenetic, Biochemistry assay)
- Randomization and attribution of treatment for the fisrt study period at home: (day -4, -3, -2, -1) 4 days of oral acetaminophen and [N-acetylcysteine or placebo] according to the randomization plan.
At day -3, -2 and -1 a salivary sample will be done to control the treatment compliance.
Day 0 at Clinical Pharmacology Center Clinical examination Measurement of the basal pain thresholds and pain evaluation (Visual Analog Scales) Blood and urinary sample (acetaminophen and GSH assay)
T0 : Administration of product: acetaminophen and [N-acetylcysteine or placebo]
T0+1H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales)
T0+2H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) and Blood sample (acetaminophen assay)
T0+3H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales)
T0+4H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) and Blood and urinary sample (acetaminophen, GSH, biochemistry assay)
- Lunch before departure
2 weeks of wash-out
Period 2 : To Day 17 to Day 21
Same of period 1. Subject who receives N-acétylcystéine in period 1 will receive placebo in second period and vice versa.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Clermont-Ferrand, Frankreich, 63003
- CHU de Clermont-Ferrand
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male
- Between 18 and 45 years old
- Without treatment during the 7 days before inclusion specially no use of antalgic and anti-inflammatory
- Cooperation and understanding enough to conform to the study obligations -Having given free, informed written consent
- Affiliated at system of French social security
- Inscription or acceptation of inscription in the national register of volunteers involved in trials.
Exclusion Criteria:
- Patient with one or many contraindication for the administration of the trial's products,
- Patient that have taken N-acetylcysteine as bronchial thinner during the last 3 days,
- Patient with medical or surgical history judged by the investigator or his representative as being not compatible with the clinical trial
- Patient with disease progression during inclusion,
- Patient with excessive consumption of alcohol, tobacco (+ than 10 cigarette/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cup a day) or any addiction to drugs,
- Patient with a heat pain mean threshold during training higher or equal to 46.5°C,
- Patient who participated in another clinical trial, located in exclusion period or received benefits > 4500 euros during 12 months before the beginning of trial,
- Patient with cooperation and understanding that do not allow him to follow the trial,
- Patients with minor or under guardianship,
- No affiliation at system of French social security
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: acetaminophen
The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine. The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine
|
|
Placebo-Komparator: placebo
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pain intensity using Visual Analog Scales (VAS) succeeding thermic stimulations at the threshold temperature +3°C before (T0-1h) and after acetaminophen's administration
Zeitfenster: At day 0
|
Pain intensity using Visual Analog Scales (VAS) succeeding thermic stimulations at the threshold temperature +3°C before (T0-1h) and after acetaminophen's administration (T0+1h, T0+2h, T0+3h, T0+4h).
|
At day 0
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Blood glutathione GSH concentration
Zeitfenster: At day 0
|
Blood glutathione GSH concentration at J0 T0-1h and J0 T0+4h
|
At day 0
|
Blood of acetaminophen concentration and its metabolites
Zeitfenster: at day 0
|
Blood of acetaminophen concentration and its metabolites at J0 T0-1h, T0+2h, and T0+4h.
|
at day 0
|
Urinary assay of the rate of acetaminophen and its metabolites
Zeitfenster: at day 0
|
Urinary assay of the rate of acetaminophen and its metabolites at J0 T0-1h, and T0+4h.
|
at day 0
|
Pharmacogenetic dosage of enzymes involved in glutathione metabolism
Zeitfenster: at day 4
|
at day 4
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Agenten des peripheren Nervensystems
- Antivirale Mittel
- Analgetika
- Agenten des sensorischen Systems
- Analgetika, nicht narkotisch
- Antipyretika
- Schutzmittel
- Atemwegsmittel
- Antioxidantien
- Gegenmittel
- Radikalfänger
- Expektorantien
- Paracetamol
- Acetylcystein
- N-Monoacetylcystin
Andere Studien-ID-Nummern
- CHU-0202
- 2013-000668-27
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
ItalfarmacoAbgeschlossenBecker-MuskeldystrophieNiederlande, Italien